信息开放的医药?

伦敦——

近几年来,制药业的新药品开发进程滞缓,生产力低下,对此,人们给予了极大的关注。作为目前大型制药公司赖以开发新药品的渠道,生物科技公司也受到这种创新危机的影响。

这促使人们对生物医学研发过程展开全面的审视;同时,制药公司在努力削减成本,提高生产效率和生产力,采取的措施包括公司合并、重组及多达上万人的裁员。但所有这些举措似乎都没能带来制药公司生存与繁荣所需要的彻底的转变。

To continue reading, please log in or enter your email address.

To read this article from our archive, please log in or register now. After entering your email, you'll have access to two free articles from our archive every month. For unlimited access to Project Syndicate, subscribe now.

required

By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in

http://prosyn.org/INJhkBB/zh;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.